UGT1A1 and neuroendocrine carcinoma: The strength of our study lies in that it is the first study of its kind to provide a multifaceted review of different aspects of nal-IRI treatment in NEC patients—efficacy, safety, and their correlation with the UGT1A1*28 allele variation.